For research use only. Not for therapeutic Use.
<p style=/line-height:25px/>NBD-557 is a potentially HIV-1 inhibitor.<br>IC50 Value:<br>Target: HIV<br>NBD-557, is small molecule organic compounds with drug-like properties. It showed potent cell fusion and virus-cell fusion inhibitory activity at low micromolar levels. A systematic study showed that NBD-557 target viral entry by inhibiting the binding of HIV-1 envelope glycoprotein gp120 to the cellular receptor CD4 but did not inhibit reverse transcriptase, integrase, or protease, indicating that they do not target the later stages of the HIV-1 life cycle to inhibit HIV-1 infection. NBD-557 potent inhibitors of both X4 and R5 viruses tested in CXCR4 and CCR5 expressing cell lines, respectively, indicating that its anti-HIV-1 activity is not dependent on the coreceptor tropism of the virus. A surface plasmon resonance study, which measures binding affinity, clearly demonstrated that NBD-557 bind to unliganded HIV-1 gp120 but not to the cellular receptor CD4. NBD-557 was active against HIV-1 laboratory-adapted strains including an AZT-resistant strain and HIV-1 primary isolates, indicating that NBD-557 can potentially be further modified to become potent HIV-1 entry inhibitors.</p>
Catalog Number | I003204 |
CAS Number | 333352-59-3 |
Synonyms | N/’-(4-bromophenyl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)oxamide |
Molecular Formula | C17H24BrN3O2 |
Purity | ≥95% |
Target | HIV |
Solubility | 10 mM in DMSO |
Storage | Store at -20°C |
Reference | <p style=/line-height:25px/> |